Document is current
Any future updates will be listed below
-
Authors
Lim, Su Yin
Shklovskaya, Elena https://orcid.org/0000-0002-6155-1020
Lee, Jenny H.
Pedersen, Bernadette
Stewart, Ashleigh
Ming, Zizhen
Irvine, Mal
Shivalingam, Brindha
Saw, Robyn P. M. https://orcid.org/0000-0002-3354-806X
Menzies, Alexander M.
Carlino, Matteo S.
Scolyer, Richard A. https://orcid.org/0000-0002-8991-0013
Long, Georgina V. https://orcid.org/0000-0001-8894-3545
Rizos, Helen https://orcid.org/0000-0002-2094-9198
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1093017, 1128951, 1130423, 2012860)
- License Information
-
More Information
Article History
Received: 25 June 2022
Accepted: 23 February 2023
First Online: 18 March 2023
Competing interests
: M.S.C. is a consultant advisor to MSD, BMS, Novartis, Roche, Pierre Fabre, Sanofi, Merck Serono, Nektar, Eisia, and Ideaya and received honoraria from MSD, BMS, and Novartis. J.H.L. has received honoraria from AstraZeneca and travel support from BMS and Novartis. R.A.S. has received fees for professional services from F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, and GlaxoSmithKline. G.V.L. is a consultant advisor for Aduro Biotech Inc, Agenus Inc, Amgen Inc, Array Biopharma Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Evaxion Biotech A/S, Hexel AG, Highlight Therapeutics. S.L., Merck Sharpe & Dohme, Novartis Pharma AG, OncoSec, Pierre Fabre, QBiotics Group Limited, Regeneron Pharmaceuticals Inc, SkylineDX. B.V., Specialised Therapeutics Australia Pty Ltd. A.M.M. has participated in advisory boards for BMS, MSD, Novartis, Roche, and Pierre Fabre. The remaining authors declare no competing interests. R.P.M.S. has received honoraria for advisory board participation from MSD, Novartis, and Qbiotics and speaking honoraria from BMS and Novartis.
